BioRN is back after a long summer break:
Festival Fever in Heidelberg: Life Science Week is rolling!
After a relaxing summer break, we are in action with fresh energy and have already completed an M2M session with our member Mazars. Watch therecordingand learn about Mazars expertise.
This week we are in Festival Fever:
Starting with the GRAND OPENING DAY BioLabs Heidelberg under the motto "Build to empower Life Science start-ups in Germany/Europe on Wednesday 27 we are looking forward to celebrate with the entire BioLabs team.
On Thursday 28 the Life Sciences Investors' Day Heidelberg open its doors at the Business Development Center Heidelberg, facilitating the presentation of the latest breakthroughs in lifescience and opportunities to invest and networking with lifescience enthusiasts + potential future partners.
And the best comes with the rest: We are looking forward seeing you at our BioRN Annual Conference on Friday 29. With more than 350 registered participants and 20 exhibitors once again, you can expect a great atmosphere with many enriching conversations! Don't miss the highlight of the year in the Life Science ecosystem Rhine-Neckar! Registration is still open!
There is a lot happening in the life science ecosystem and we are very proud to be able to share our expertise in our article in the current issue of EMBO reports entitled: >>Supporting a vibrant entrepreneurial ecosystem: High density, critical mass, and effective strategies underpin the success of innovative lifescience ecosystems<<. If you are interested in receiving a copy, get in contactwith us!
Enjoy more news from our network and mark your calendar for the upcoming events!
Stephanie Füller
PR Manager
BioRN Life Science Cluster Rhine-Neckar
01 | Research Highlights & News
02 | New Members
03 | Events Spotlight
04 | Event Calendar & Discounts
05 | Open Positions
01| Research Highlights & News
AaviGen raises 17M € in second financing round to advance precision gene therapies for heart failure[more]
Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma [more]
Ariadne.ai - Looking for beta testers for new spatial biology software-as-a-service (SaaS) plattform [more]
Ascendis Pharma Launches SKYTROFA® (lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency [more]
ERC starting grants for two EMBL Heidelberg researchers [more]
Heidelberg Pharma:
Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with Lead Candidate HDP-101 [more]
Heidelberg Pharma’s Partner Takeda Reached Development Milestone [more]
Heidelberg University:
How Ribosome Production and Cell Proliferation Rate Are Linked [more]
Virus Enzyme Links RNA Chains to Host Proteins [more]
Heidelberg University Hospital (UKHD): Valuable Funding from ERC for Heidelberg Early-Career Researcher [more]
PAICON: How can big Data in Medical Research eliminate Health Disparities? [more]
02 | New Members
ACROBiosystems offers a wide array of life sciences tools, reagents, and instruments to serve customers spanning over 7000 pharmaceuticals, CRO/CDMO, research institutions, and hospitals across 70 countries. ACROBiosystems’ brands include FLAG, Star Staining, ViruStop, Aneuro, ComboX, GENPower, and many others. Its main products and services are recombinant proteins, kits, antibodies, scientific services, and other related products. ACROBiosystems employs a strict quality control system for its products that are used in biopharmaceutical research and development, production, and clinical application. This includes targeted discovery and validation, candidate drug screening/optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics.
KyooBe Tech is a specialized technology developer focusing on the commercialization of innovative pharmaceutical production technologies. The main application areas of their technologies are pathogen inactivation and cell and gene therapy manufacturing. INACTIVATE, the first product line entering the market in 2024, aims to inactivate pathogens with low-energy electron irradiation. Since 2022, KyooBe Tech has successfully been operating a test platform to optimize the process parameters for individual product irradiation applications. MOSAIC is a modular manufacturing platform for personalized medicine. The vision is, to offer individual cell and gene therapy on an industrial scale.
NEUWERK specializes in providing comprehensive legal support to the life sciences sector. The Life Sciences Group consists of expert lawyers with deep industry knowledge, capable of addressing all legal needs of life sciences clients, be it procedural or industry-specific. Clients include pharmaceutical and biotech companies, startups, medical device manufacturers, hospitals, research institutions, tech companies, investors, and family businesses. For more information please visit www.bio.law, NEUWERK's website for life science companies and their investors.
Technologiepark Mannheim GmbH (TPMA). The TPMA is an investor in the Mannheim Medical Technology Campus (MMT Campus), which is located in the immediate vicinity of the University Medical Centre Mannheim and continues to grow. The Technology Park is an ideal business location for the research and development of new medical technologies and products due to its immediate proximity to research, business, and the hospital. The TPMA takes care of the development and realization, as well as the ongoing operation and marketing, and offers you the ideal location on the MMT campus – whether as an existing company or a new start-up.
03 | Events Spotlight
04 | Event Calendar & Discounts
MVA Good Morning Meeting – Accelerated ADC development via integrated antibody discovery platform October 5, 2023 - Copenhagen, Denmark >>
Presenting Non-Confidential Data in Partnering Discussions October 5, 2023 - Leiden, NL and virtual >>
Bayer's Expert Mondays: Why Early Market Access Planning is a Good Investment & 10-min. deep-dive on Cell & Gene October 09, 2023 - Online >>
Rudolf Mößbauer Colloquium with Henrik Kaessman (Heidelberg University) October 10, 2023 - Heidelberg >>
Festival of Biologics 2023 October 10-12, 2023 - Basel, CH
20 % discount for the on-site conference for BioRN Members >>
Spatial Multiomics Summits October 2023 October 10-13, 2023 - Paris, Madrid, Frankfurt or London >>
Regulatorik Nachgefragt: Neues aus dem Patentrecht October 12, 2023 - Online >>
Bayer's Expert Mondays: How to Set Up a Credible Business Case October 16, 2023 - Online >>
Conference: AI inSCIEde out - Advances, Issues & Opportunities October 16-17, 2023 - Heidelberg, Germany >>
Moving From Molecular Visualization to Simulation: The Impact of Computer-Augmented Molecular Design October 17, 2023 - Online >>
Advanced Therapies Summit 2023 October 19, 2023 - Leuven, Belgium
October 16-18 & 20 - Online Matchmakinh
20 % discount for the on-site conference for BioRN Members >>
Bayer's Expert Mondays: Leaps @ Bayer: Funding the 10 Leaps October 23, 2023 - Online >>
Meet & Match – Hospital of the future October 24, 2023 - Mannheim, Germany >>
Rudolf Mößbauer Colloquium with Sinem Saka (EMBL) October 24, 2023 - Heidelberg >>
1st European Health Data Protection Congress October 24-25, 2023 - Paris, France >>
Virology Seminar: Obstacles and potential benefits of antibodies to AAV capsids - the Sydney experience stemming from SMA gene therapy October 31, 2023 - Heidelberg >>
Bio-Europe November 06-08, 2023 - Munich, Germany
900 € discount until 28th July and 10 % discount on later registration for BioRN Members >>
Future Medicine Science Match 2023 November 09, 2023 - Berlin, Germany
Free tickets upon request available for BioRN Members >>
7th Immunotherapies & Innovations for Infectious Diseases Congress 2023 - I4ID2023 November 22-23, 2023 - Lyon, France
10 % discount for BioRN Members >>
05 | Open Positions
BioRN: Team Mitglied (m/w/d): Projektmanager Communication & Strategieentwicklung [more]
You are currently viewing a placeholder content from Mailchimp. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
